Urticaria is an inflammatory skin disorder that affects up to 20% of the world population at
some point during their life. It presents with wheals, angioedema or both due to activation …

Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

This update and revision of the international guideline for urticaria was developed following
the methods recommended by Cochrane and the Grading of Recommendations …

Background Chronic spontaneous urticaria (CSU) is inadequately controlled in many
patients and greatly affects quality of life. Remibrutinib, a highly selective, oral, novel …

This evidence‐and consensus‐based guideline was developed following the methods
recommended by Cochrane and the Grading of Recommendations Assessment …

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and
middle‐aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and …

Background and objectives Urticaria is a frequent skin condition, but reliable prevalence
estimates from population studies particularly of the chronic form are scarce. The objective of …

Background Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and
frustrating for patients and physicians. Real‐world evidence for the burden of CSU is limited …

Background In the majority of patients with chronic spontaneous urticaria, most currently
available therapies do not result in complete symptom control. Ligelizumab is a next …

This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the
primary effector cell in urticaria. Mast cells are located in the upper dermis, the ideal situation …